Anteris Technologies Global (NASDAQ:AVR) Stock Rating Upgraded by Barclays

Anteris Technologies Global (NASDAQ:AVR) was upgraded by stock analysts at Barclays to a “hold” rating in a research note issued on Wednesday, Zacks reports.

A number of other research firms have also commented on AVR. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Friday, August 14th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.00.

Anteris Technologies Global Stock Down 2.8%

NASDAQ AVR opened at $6.63 on Wednesday. The firm has a 50-day moving average price of $8.41 and a two-hundred day moving average price of $8.03. Anteris Technologies Global has a 12-month low of $3.30 and a 12-month high of $11.06. The company has a market capitalization of $646.16 million, a P/E ratio of -3.40 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last announced its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. During the same period in the prior year, the business posted ($0.58) earnings per share. Equities analysts expect that Anteris Technologies Global will post -1.21 EPS for the current year.

Insider Transactions at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was acquired at an average price of $7.51 per share, with a total value of $4,869,897.05. Following the purchase, the insider directly owned 12,778,380 shares in the company, valued at approximately $95,965,633.80. This trade represents a 5.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have purchased 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. 4.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Anteris Technologies Global

Hedge funds have recently added to or reduced their stakes in the stock. Cetera Investment Advisers lifted its stake in shares of Anteris Technologies Global by 64.7% in the 1st quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after acquiring an additional 6,500 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Anteris Technologies Global by 12.6% during the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock valued at $382,000 after purchasing an additional 7,688 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Anteris Technologies Global during the second quarter worth about $78,000. Bartlett & CO. Wealth Management LLC increased its stake in shares of Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after buying an additional 8,200 shares during the period. Finally, Abel Hall LLC bought a new position in Anteris Technologies Global in the 1st quarter valued at approximately $63,000.

Key Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder continued buying. L1 Capital purchased 272,695 AVR shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48%. This follows several additional purchases in late September and early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
• Neutral Sentiment: Barclays initiated coverage with a Hold-equivalent view. Barclays’ reported “Hold” or “Equal Weight” stance suggests the firm sees limited near-term evidence for a stronger bullish recommendation. The coverage provides additional visibility but is unlikely to be a major catalyst by itself. Barclays AVR rating report
• Neutral Sentiment: Share and incentive-plan records were updated. Anteris reported changes involving CHESS Depositary Interests and employee equity incentives. These administrative updates do not provide a new clinical or commercial catalyst, though investors will monitor their effect on the share count. Anteris CDI and equity incentive update
• Negative Sentiment: Expanded unquoted equity may raise dilution concerns. The employee incentive-plan announcement adds to investor attention on potential future share issuance. For a clinical-stage company that is not yet profitable, the prospect of additional equity compensation or dilution can weigh on sentiment. Anteris employee incentive-plan announcement

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.